Introduction {#Sec1}
============

African American breast cancer patients are more likely than breast cancer patients from other populations to be affected at a young age; to develop aggressive, triple-negative breast cancers (TNBC) that lack expression of estrogen, progesterone, and HER2 receptors; and to die from their disease \[[@CR1]--[@CR4]\]. Furthermore, patients from all populations with inherited mutations in *BRCA1* (MIM 113705) and *BRCA2* (MIM 600185) are more likely to be diagnosed at a young age, and especially among *BRCA1* carriers, to develop TNBC \[[@CR5], [@CR6]\]. Thus, one potential contributor to the higher incidence of early-onset aggressive breast cancer among African American patients may be a previously undefined higher burden of inherited breast cancer in this population. High frequencies of mutations in *BRCA1* and *BRCA2* have already been observed in breast cancer patients of African ancestry from Nigeria \[[@CR7]\] and from the Bahamas \[[@CR8]\]. In addition to *BRCA1* and *BRCA2*, other genes that harbor mutations that predispose to breast cancer include *PALB2* \[[@CR9], [@CR10]\], *CHEK2* \[[@CR11]\]*, ATM* \[[@CR12]--[@CR15]\]*, BARD1* \[[@CR16], [@CR17]\]*, RAD51C* \[[@CR18]\]*, RAD51D* \[[@CR19]\]*, TP53* \[[@CR20]\], and *PTEN* \[[@CR21]\]. The relationship between aggressive young-onset breast cancer and mutations in these other genes is not yet well characterized.

Advances in DNA sequencing technologies have yielded assays that efficiently and cost-effectively screen multiple genes at the same time. One such assay, BROCA, was designed and validated for the simultaneous detection of mutations in multiple genomic regions encompassing all known and emerging breast cancer susceptibility genes \[[@CR22], [@CR23]\]. BROCA detects, in a single assay, all classes of mutations: single nucleotide variants, small insertions and deletions (indels), and large genomic rearrangements.

To investigate the genomic basis of early-onset breast cancer in African American women, we examined the frequencies of inherited mutations in cancer genes in self-reported African American patients ascertained through a cancer genetics clinic at a single tertiary-care medical center.

Patients and methods {#Sec2}
====================

Patients {#Sec3}
--------

Participants were women who self-reported as African American, who were diagnosed with primary invasive breast cancer, and who were ascertained at The University of Chicago Medicine Breast Program and the Cancer Risk Clinic between 1993 and July 2013. The University of Chicago serves a population catchment area that is predominantly African American; approximately 35 % of ethnically identified samples in our Breast Program biospecimen bank are derived from African Americans. Implementation of dedicated consenting led to a remarkably high consent rate of nearly 95 % on our biospecimen banking protocol. If related affected persons appeared on the registry, only the first to be listed was included. Of 502 unrelated African American women with a diagnosis of invasive breast cancer, DNA was available from 370 patients. Among them, a total of 289 African American patients were included in the present study based on meeting at least one of the following criteria: breast cancer diagnosis before age 45; personal history of both breast and ovarian cancer; TNBC; or family history of breast cancer before age 60 or of ovarian cancer at any age in a first or second degree relative. The Institutional Review Boards (IRB) at The University of Chicago and the University of Washington approved the study. Patients had been consented for use of their samples for future genomic analysis. Permission for use for this study was obtained from the IRB. BROCA testing results were returned to participants according to their preference of knowing or omitting the information.

Mutation detection {#Sec4}
------------------

From each subject, 3 ug of DNA were used to prepare paired-end libraries with 150-bp inserts, which were hybridized to a custom pool of oligonucleotides designed to capture 48 genomic regions, and sequenced as previously described \[[@CR22], [@CR23]\]. For this project, only unambiguously damaging mutations in breast cancer genes *BRCA1, BRCA2*, *PALB2, CHEK2, ATM, BARD1, RAD51C, RAD51D, TP53,* and PTEN were evaluated. Single base-pair substitutions and indels \[[@CR23]\] and large copy number variants (CNVs) \[[@CR24]\] were identified as previously described. Unambiguously damaging mutations were defined as truncations from any source, complete gene deletions, splice mutations shown experimentally to yield truncations, and missense mutations shown experimentally to disrupt protein function. Single base-pair substitutions and indels were validated by independent PCR amplification and Sanger sequencing. CNVs were validated by real-time PCR using TaqMan probes (Life Technologies, Carlsbad, CA, USA) targeting the deleted or duplicated region. Qualifying patients were included in the study regardless of previous genetic testing; for those with prior genetic testing, sequencing and analysis was repeated, blind to previous results.

Statistic analysis {#Sec5}
------------------

Proportions of mutation carriers and exact 95 % confidence intervals (CI) were estimated using binominal distribution. Fisher's exact tests were used to examine whether mutation proportions vary across age groups or among patients meeting different numbers of eligibility criteria.

Results {#Sec6}
=======

A total of 289 patients qualified for the study; their clinical features are shown in Table [1](#Tab1){ref-type="table"}. Approximately, half of qualifying patients met more than one selection criterion, as illustrated in Fig. [1](#Fig1){ref-type="fig"}a. BROCA yielded \>400-fold median coverage with 94 % of targeted bases covered \>50-fold and 99.8 % of bases covered \>10-fold. Sixty-eight damaging mutations were identified in 65 (22 %, 95 % CI 18--28 %) of the 289 subjects. All mutations previously identified and published \[[@CR25], [@CR26]\] were independently identified by BROCA. The proportions of patients with unequivocally damaging mutations were 26 % (47/180; 95 % CI 20--33 %) of those with breast cancer diagnosis before age 45, 25 % (26/103; 95 % CI 17--35 %) of those with TNBC, 29 % (45/156; 95 % CI 22--37 %) of those with a qualifying family history, and 57 % (4/7; 95 % CI 18--90 %) of the small group with both breast and ovarian cancer (Fig. [1](#Fig1){ref-type="fig"}b).Table 1Clinical features of 289 African American patients with primary invasive breast cancer selected for young age at diagnosis, family history, or TNBCNProp.Age at breast cancer diagnosis \< 451800.62 45--59850.29 60+240.08Personal history of ovarian cancer Yes70.02 No2820.98Cancer in 1° or 2° relative Breast cancer dx \< 601440.50 Ovarian cancer, any age290.10 Male breast cancer, any age50.02 Neither670.23 Unknown640.22Tumor hormone receptor statusEstrogen receptor (ER) Positive1090.38 Negative1350.47 Unknown460.16Progesterone receptor (PR) Positive830.29 Negative1530.53 Unknown530.18Her2/neu Positive350.12 Negative1770.61 Unknown770.27Triple negative (TNBC) Yes1030.36 No1310.45 Unknown550.19Stage 1690.24 2910.31 3560.19 4150.05 Unknown580.20Grade I90.03 II710.25 III1280.44 Unknown810.28All patients2891.00Fig. 1Frequencies of inherited mutations in breast cancer genes among African American breast cancer patients with young age at diagnosis, family history of breast or ovarian cancer, or triple negative breast cancer (TNBC). **a** Numbers of patients meeting each of the study criteria. All patients were diagnosed with primary invasive breast cancer and self-identified as African American. *FH+* indicates a first or second degree relative with breast cancer diagnosed at age \<60 or ovarian cancer at any age; *Br/Ov* indicates breast and ovarian cancer in the same subject; *Br dx \<45* indicates that the participant's breast cancer was diagnosed at age \<45; *TNBC* indicates that the breast cancer was triple negative; i.e., lacking estrogen and progesterone receptors and Her2. The study included 289 patients in all. **b** Proportions of patients with an unequivocally damaging mutation in a breast cancer gene, for each group from (**a**)

The mutations were distributed among eight genes, with the most in *BRCA1* (29) and *BRCA2* (23) and the remaining in *PALB2* (3), *ATM* (5), *CHEK2* (4), *BARD1* (1), *TP53* (1), and *PTEN* (2) (Fig. [2](#Fig2){ref-type="fig"}). No truncations were present in either *RAD51C* or *RAD51D*, even among the 35 patients with personal or family history of ovarian cancer. Four mutations were large genomic deletions, three in *BRCA1* and one in *ATM*. All damaging mutations are indicated in Table [2](#Tab2){ref-type="table"}. In addition to the 68 damaging mutations, we classified two variants as unknown significance, or "VUS": *BRCA1_5160A* \>*G* (U14680) in exon 17, and *BRCA2_8614C* \>*T* (U43746) in exon 19, both predicted to alter splicing by disrupting exonic splice enhancer sites, but thus far without functional tests of patient RNA. These two variants were not included in subsequent analyses.Fig. 2Eight genes with mutations in African American breast cancer patients. A total of 68 mutations were identified, 76 % in *BRCA1* or *BRCA2* and 24 % in other breast cancer genesTable 2Germline mutations in African American patients with primary breast cancer with young age at diagnosis (Br dx \<45), family history of breast cancer younger than age 60 (FH Br \<60) or of ovarian cancer (FH Ov), or triple-negative breast cancer (TNBC)Patient BROCA IDAge dxGeneMutation (BRCA1 U14680; BRCA2 U43746)Br dx \<45FH Br \<60FH OvSelf Br+OvTNBCBreast Ca typeERPRHER2StageGrade39034BRCA1del exons 1--19 (\>64,761 bp)YesYesYesNoYesIDCNegNegNeg2III38939BRCA1C61YYesYesNoNoYesIDCNegNegNeg1II17949BRCA1C64GNoYesNoNoUnkBr nos37234BRCA1943ins10YesYesNoNoNoIDCPosNegNeg1III22734BRCA1943ins10YesUnkUnkNoYesIDCNegNegNeg1III39133BRCA1Q491XYesYesYesNoYesIDCNegNegNeg128537BRCA11759delATAAYesNoNoNoYesIDCNegNegNeg2II34734BRCA11832delAGAATYesYesNoOv 46NoIDCPosNeg2III34343BRCA11832delAGAATYesYesNoNoUnkBr nos39348BRCA13347delAGNoYesNoNoYesIDCNegNegNeg2III20142BRCA1S1212XYesYesNoNoUnkBr nos41138BRCA1E1222XYesYesNoNoYesIDCNegNegNeg1III42737BRCA1K1290XYesUnkUnkNoUnkBr nos33828BRCA13883insAYesYesNoNoNoIDCPosPosNeg2III45237BRCA13890delGGinsCYesNoNoNoYesIDCNegNegNeg3III14134BRCA1Q1604XYesUnkUnkNoUnkBr nosNegNeg2III25546BRCA1del ex17 (3,118 bp)NoYesNoNoYesIDCNegNegNeg1III25143BRCA15296delGAAAYesYesYesNoUnkBr nos34538BRCA15296delGAAAYesYesYesNoUnkIDC3III38029BRCA15296delGAAAYesYesNoOv 49UnkBr nos40924BRCA15296delGAAAYesYesNoOv 45UnkIDC123429BRCA15296delGAAAYesNoNoNoNoIDCPosNegNeg2III12340BRCA15312(ivs19)(+1)G\>AYesNoYesNoYesIDCNegNegNeg2III18035BRCA1R1751XYesYesNoNoUnkBr nos34429BRCA1R1751XYesYesNoNoYesIDCNegNegNeg3III18639BRCA1M1775RYesYesYesNoUnkBr nos47360BRCA1IVS23+1G\>ANoYesNoNoYesIDCNegNegNeg1II47631BRCA1IVS23+1G\>AYesNoNoNoNoIDCPosNegNeg1III48759BRCA1del (ex 24+3UTR)NoYesNoNoNoIDCNegNegPos3III38646BRCA2746delGNoYesNoNoNoIDCPos40738BRCA2886delGTYesYesYesNoUnkBr nos45553BRCA2886delGTNoYesNoNoYesBr nos34040BRCA21433delGYesNoNoNoYesIDCNegNegNeg3II27254BRCA22808delANoYesNoNoYesIDCNegNegNeg1III26044BRCA22808delAAACYesUnkUnkNoYesIDCNegNegNeg4III33533BRCA22816insAYesYesYesNoNoIDCPosPos2III27335BRCA23034delAAACYesyesNoNoYesIDCNegNegNeg3III39742BRCA23036del4YesYesYesNoNoIDCPosPosNeg2II15721BRCA2K944XYesNoNoNoUnkIDC44166BRCA24355del4NoYesNoNoNoIDCPosPosNeg1III44738BRCA24682del4YesYesNoNoYesBr nosNegNegNeg43234BRCA24959delAYesYesYesnoYesIDCNegNegNeg1III60051BRCA25579insANoYesNoNoUnkBr nos50443BRCA25844del5YesYesNoNoYesIDCNegNegNeg2III45436BRCA25844del5YesUnkUnkNoNoIDCPosNegNeg2II49752BRCA25920delGNoYesYesNoNoIDCPosPosNeg11035BRCA25946delCTYesYesNoNoYesIDCNegNegNeg3III29040BRCA27297delCTYesUnkUnkNoYesIDCNegNegNeg1III45039BRCA2R2520XYesYesNoNoNoIDCPosPosNeg2III34251BRCA27795delCTNoYesNoNoNoBr nosPosPos143954BRCA28529delTNoYesNoOv 48UnkBr nosNeg27631BRCA2R3128X\*YesNoNoNoNoIDCPosPosPos18551ATMc.6404insTTNoUnkUnkNoYesIDCNegNegNeg1II31829ATMY2755XYesNoNoNoNoIDCPosPos330758ATMdel ex62--63 (9,769 bp)NoYesNoNoNoIDCPosPosPos1III44852BARD1S551XNoYesNoNoNoIDCPosPosNeg2III31234CHEK2R160G\*\*^\*\*^YesYesNoNoNoIDCPosPos3III26235CHEK2H186RYesNoNoNoNoIDCPosPosNeg1II10133CHEK2G210R homozygousYesUnkUnkNoYesIDCNegNegNeg3III18745PALB2758insTNoYesNonoNoIDCPosPosNeg2II15536PALB21479delCYesYesNoNoNoIDCPosPosNeg2III19160PALB23048delTNoNoNoNoYesIDCNegNegNeg3II33335PTENR335XYesNoNoNoYesIDCNegNegNeg2II24843PTENc.1027(ivs8)(−1)G\>TYesYesNoNoNoIDCPos144632TP53P278AYesUnkUnkNoNoIDCNegNegPos2II^\*^ This patient also carried an ATM (p.R248X) mutation; ^\*\*^ This patient also carried a ATM p.R457X mutation

Patients meeting more than one qualifying criteria were more likely to carry a mutation (*P* = 0.001). Proportions of patients with mutations were 15 % (22/144) of those meeting only one criterion, 25 % (29/116) of those meeting two criteria, and 48 % (14/29) of those meeting three criteria. No patients met all four criteria. The distribution of mutations gene-by-gene differed in that mutations in *BRCA1* were more frequent among patients diagnosed at age \<45 than among patients diagnosed at age ≥45 and selected on other criteria (24/180 versus 5/109; *P* = 0.016). There were no other differences in the distribution of mutations gene-by-gene among patients selected by various criteria. The prevalence of damaging mutations among familial TNBC cases was 34.0 % (16/47) versus 17.9 % (10/56) in non-familial TNBC, but this was not statistically significant (*P* = 0.071).

Three patients carried two mutations each. Patient 101 was homozygous for CHEK2 p.G210R and was diagnosed with TNBC at age 33. Patient 276 carried both BRCA2 p.R3128X and ATM p.R248X. She was diagnosed with receptor-positive breast cancer at age 31. Patient 312 carried both CHEK2 p.R160G and ATM p.R457X. She was diagnosed with stage 3, receptor-positive breast cancer at age 34.

Three patients carried mutations in genes responsible for breast cancer in the context of syndromic disease. Patient 446 carried *TP53* p.P278A. She was diagnosed at ages 32 and 36 with bilateral breast cancer. Her family history is unknown. Patient 333 carried PTEN p.R335X. She has hyperkeratosis and was diagnosed at age 35 with bilateral breast cancer, including foci of TNBC and DCIS and LCIS, and at age 46 with renal cell cancer. Her father carried the same mutation and was previously diagnosed with Cowden syndrome (MIM 158350). He developed renal cell cancer at age 53. The family includes multiple other relatives with cancer. Patient 248 carried *PTEN* c.1027(ivs8)(-1)G\>T, which alters splicing of the last exon of *PTEN*, leading to reduced stability of the *PTEN* message. She was diagnosed with breast cancer at age 43; her family cancer history is unknown.

Discussion {#Sec7}
==========

These results are based on the largest clinic-based cohort of prospectively ascertained African American breast cancer patients to undergo genomic testing of cancer genes known to be associated with inherited breast cancer. Using a more cost-effective and innovative high-throughput sequencing technology, we found that nearly one in four of patients meeting selection criteria carried an inherited damaging mutation in at least one gene. There were 57 different pathogenic mutations in eight different genes among 65 patients, supporting the clinical utility of simultaneous multi-gene testing, rather than relying on a limited mutation panel or a gene-by-gene approach. The majority of mutations were found in *BRCA1* and *BRCA2* genes. These results are consistent with data from clinic-based cohorts in other populations.

There are strengths and weaknesses to any single institution study. There is paucity of data on well-phenotyped patients of African ancestry. This study represents the first report of a large cohort of self-reported African American patients with integrated mutation results from next-generation sequencing, clinical characteristics of the patients, and tumor phenotype. Our results confirm that inherited mutations in the *BRCA1* and *BRCA2* tumor suppressor genes are still the strongest predictors of breast and/or ovarian cancer risk in women of African ancestry. It is well recognized that prevalence of mutations in both genes among breast cancer patients vary by ethnicity, study inclusion criteria, and mutation detection techniques \[[@CR27]\]. In this study, we found 10.0 % (29 out of 289) of cases carried pathogenic *BRCA1* mutations and 8.0 % (23 out of 289) of cases are *BRCA2*-positive. The prevalence of recurrent *BRCA1* and *BRCA2* mutations among selected breast cancer patients are higher in founder populations such as Ashkenazi Jewish populations where a relatively cost-effective strategy of testing for three common mutations in *BRCA1* and *BRCA2* genes currently exists \[[@CR25], [@CR28], [@CR29]\]. In a study examining *BRCA1, BRCA2*, *CHEK2*, and *TP53* in US high-risk families (95 % were of European ancestry), 9.6 and 6.5 % of probands were found to be *BRCA1* and *BRCA2* mutation carriers, and, mutation prevalence increased to 13.2 % (*BRCA1*) and 7.4 % (*BRCA2*, *CHEK2* and *TP53*) among patients \<49 years old, respectively \[[@CR30]\]. We have previously reported high mutation rates among clinic-based cohorts of women of African ancestry with early-onset breast cancer (≤45 years) \[[@CR25]\]. In a population-based study from North California Breast Cancer Family Registry, *BRCA1* mutation prevalence were 1.3, 2.2 and 3.5 % in African American, non-Hispanic and Hispanic patients overall but 16.7 % in African American cases diagnosed under the age of 35 years old \[[@CR28]\]. Among 46,276 subjects (78.3 % Western European ancestry and 3.8 % African ancestry) tested by Myriad Genetics, Inc., *BRCA1* and *BRCA2* mutation prevalence was 10.2 and 5.7 % in the African ancestry group, respectively versus 6.9 and 5.2 % in populations of Western European ancestry \[[@CR31]\]. In a genetic counseling TNBC cohort, *BRCA1* and *BRCA2* mutation prevalence has been reported to differ by populations \[[@CR32]\]; 50 % in Ashkenazi Jewish women, 33.3 % in Caucasian women, and 20.4 % in African American women which is consistent with what we found in this study. A limitation of our study is that there is significant genetic diversity in the African Diaspora and results from our single institution study are not generalizable to the general population. Larger studies using next-generation sequencing in diverse populations are needed to derive true estimates of the burden of inherited breast cancer in underserved and understudied populations.

Next-generation sequencing assays promise to accelerate progress in screening for somatic as well as inherited genetic mutations among cancer patients. Several laboratories now offer genomic testing with reasonable turn around times, but the clinical utility of these cancer gene panels remain in question. BRCAplus, a high-risk breast cancer diagnostic assay, includes six breast cancer genes: *BRCA1*, *BRCA2*, *TP53*, *PTEN*, *STK11*, and *CDH1* \[[@CR33]\] and has been evaluated in more than 3,000 clinical samples referred to Ambry Genetics for mutation detection. The result showed that *BRCA*1 and *BRCA2* mutations were found in 5.7 % of the patients and contributed 85 % of all the mutations identified. Another 27 gene targeted sequencing panel has also been evaluated in 708 hereditary breast and/or ovarian cancer patients \[[@CR34]\]. In total, 109 germline mutations were detected, among them, 37 in *BRCA1*, 32 in *BRCA2*, 4 in *TP53*, and 36 in other genes. Similarly, *BRCA1* and *BRCA2* mutations accounted for around 60 % of the positive test results. Using BROCA in this study, 80 % of the cases had mutations in *BRCA1* and *BRCA2* while mutations in *PALB2, CHEK2*, *BARD1*, *ATM*, *PTEN*, and *TP53* were found in the remaining 20 %. Given the diversity in ethnic populations, mutation detection methods, breast cancer genes included, degree of disease risk, sample size, and so on, the estimate of the prevalence of mutations in the rapidly expanding number of cancer susceptibility genes will also vary. Nonetheless, these massively parallel sequencing panels indeed prove their useful implementation in clinics and confirm that genes involved in DNA repair pathways, including *BRCA1* and *BRCA2* are the major genes contributing to inherited breast and ovarian cancer in African American populations \[[@CR10]\].

The limited information about family history of cancer in several of these patients reflects a general problem. Of patients meeting selection criteria other than family history (i.e., selected for young age at diagnosis or TNBC), 48 % (64/133) had very limited information about cancers in previous generations of their families. This problem likely reflects historical disparities in access to medical care and strongly suggests that criteria other than family history should be widely recognized by clinicians and sufficient for referral for genomic testing. As has been demonstrated in Ashkenazi Jewish women and women of European ancestry \[[@CR32]\], our results suggest that African American women with young age at onset, family history of breast or ovarian cancer, or TNBC could benefit very substantially from genomic testing. Identifying inherited mutations in breast cancer patients is important for at least three reasons. Patients with inherited mutations in genes involved in DNA repair pathways may be treated with synthetic lethal therapeutic approaches based on poly-ADP-ribose polymerase inhibitors (PARPi) \[[@CR35]--[@CR37]\]. In addition, women with inherited mutations in *BRCA1,BRCA2*, and *PALB2* should be advised about risk-reducing salpingo-oophorectomy \[[@CR38]\]. Furthermore, each breast cancer patient with inherited disease represents a family including as-yet-unaffected sisters and daughters and nieces for whom genetic knowledge can empower cancer prevention. Increased focus on cancer control and prevention to improve population health has the potential to reduce cost of care for advanced disease in underserved populations.

Despite its limitation as a single institution study, this study speaks to a fundamental problem of disparities in breast cancer outcomes among African American women. African American breast cancer patients are more likely than breast cancer patients of other ancestries to be affected at a young age; to develop aggressive breast cancers; and to die from their disease \[[@CR1], [@CR3], [@CR4]\]. It is also known that patients with inherited mutations in *BRCA1* are more likely to be diagnosed at a young age \[[@CR5], [@CR6]\]. The distribution of genetic and non-genetic risk factors for breast cancer is not uniform across populations and there is significant heterogeneity in breast cancer. It is possible that one potential contributor to the higher incidence of aggressive early-onset breast cancer among African American patients is a higher burden of previously understudied inherited mutations in breast cancer susceptibility genes. In order to test this hypothesis rigorously, taking into consideration the significant genetic diversity in the African Diaspora, it would be necessary to evaluate large, population-based cohorts of breast cancer patients of African and other ancestries, including both comprehensive genomic analysis and thorough characterization of patient history, tumor characteristics, treatment, and survival. Our study addressed the converse question: the frequency of mutations given family history or young-onset aggressive breast cancer. We suggest that the mutation frequency of approximately 25 % among African American patients with these features underscores the need for larger studies among women from diverse populations.

Heretofore, high cost and insurance coverage has been a major barrier to incorporating genomic testing into clinical cancer care. Targeted capture and multiplexed sequencing offers the capacity to sequence multiple relevant genes at once, in a single test, rather than having to order sequential genetic tests at a cost of thousands of dollars per gene. The cost of genetic testing for breast cancer predisposition should drop quickly in a competitive marketplace, allowing more equitable access. Diffusion of genetic technologies in diverse populations has the potential to accelerate precision medicine, improve cancer prevention, lower costs of cancer care, and reduce disparities in health outcomes.
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